The GRPR-targeting antagonist peptide RM1 was more stable than the agonist AMBA in blood serum, and adding gentisic acid significantly extended its shelf life for potential prostate cancer imaging use.
Antagonist > AgonistThe RM1 antagonist degraded more slowly than the AMBA agonist in mouse, canine, and human sera, making it the more promising imaging candidate
What the researchers found
The GRPR-targeting antagonist peptide RM1, when labeled with lutetium-177, proved more stable than the agonist peptide AMBA in mouse, canine, and human sera. Degradation followed the order: mouse sera (fastest) > canine > human sera (slowest), meaning the peptide lasts longest in human blood.
Higher radioconcentrations caused faster degradation of 177Lu-labeled RM1 during storage at 2–8°C. Adding stabilizers significantly improved shelf stability, with gentisic acid outperforming ascorbic acid. These findings support RM1 antagonist as the more promising candidate for both PET imaging and potential therapy of prostate cancer.
Why it matters
For peptide-based cancer imaging to work in the clinic, the radiolabeled peptide must remain stable long enough to reach the tumor and produce a clear image. This study addressed a practical barrier — figuring out how to keep these peptides from degrading — and identified both a better peptide candidate (antagonist over agonist) and effective stabilizers that could extend shelf life.
The numbers in context
2 peptides compared (AMBA agonist vs RM1 antagonist) · 177Lu radiolabel · stability tested in acetate buffer + mouse, canine, and human sera · gentisic acid > ascorbic acid as stabilizer
How the study worked
Researchers compared the stability of two lutetium-177-labeled peptides — the AMBA agonist and RM1 antagonist — that target the gastrin-releasing peptide receptor found on prostate cancer cells. They tested stability in acetate buffer and in sera from mice, dogs, and humans at different radioconcentrations and storage temperatures. They also tested whether adding ascorbic acid or gentisic acid could prevent degradation.
Who was studied
In vitro study using mouse, canine, and human sera
What this study cannot tell us
This is an in-vitro stability study — it tests how well the peptides hold up in buffer and blood serum, not how well they perform in living patients. No imaging or therapeutic outcomes were measured. The study focused on lutetium-177 labeling specifically, so results may differ with other radioisotopes.
How to read the evidence
This is a preliminary in-vitro study focused on peptide stability rather than clinical outcomes. It provides useful pharmaceutical development data but no direct evidence of patient benefit.
When this study was published
Published in 2019, this study remains relevant as GRPR-targeting peptide imaging agents continue through clinical development for prostate cancer.
The bigger picture
Targeted peptide imaging is a growing field in cancer diagnostics and theranostics — using the same peptide to both find and treat tumors. Stability is one of the biggest practical hurdles for getting peptide radiopharmaceuticals from the lab to the clinic. This work helps solve that problem for GRPR-targeting compounds, which are being developed for prostate cancer detection alongside the more established PSMA-targeting agents.
Questions still open
- How does the improved stability of RM1 translate to image quality and tumor uptake in human patients?
- Could gentisic acid stabilization be applied to other peptide radiopharmaceuticals beyond GRPR-targeting compounds?
- How does GRPR-targeted imaging compare to PSMA-targeted imaging for prostate cancer detection?
Common questions
What is the gastrin-releasing peptide receptor (GRPR) and why target it for prostate cancer?
Why does an antagonist peptide work better than an agonist for imaging?
Read the original research
Stability Evaluation and Stabilization of a Gastrin-Releasing Peptide Receptor (GRPR) Targeting Imaging Pharmaceutical.
Molecules (Basel, Switzerland), 24(16)
Citation
Ghosh, Arijit; Woolum, Karen; Kothandaraman, Shankaran; Tweedle, Michael F; Kumar, Krishan. (2019). Stability Evaluation and Stabilization of a Gastrin-Releasing Peptide Receptor (GRPR) Targeting Imaging Pharmaceutical.. Molecules (Basel, Switzerland), 24(16). https://doi.org/10.3390/molecules24162878